TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00790595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
Study: NCT01994070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electrical-first
Description: Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical-first
Description: Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
Study: NCT01770080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euminz®
Description: 3 to 5 time topical use of study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 to 5 time topical use of study drug.
Study: NCT00884195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Journaling
Description: Participants will be asked to write down 5 things every day for which they are grateful.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Journaling
Description: Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
Study: NCT04340102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BecomeAnEx
Description: This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
Study: NCT05069909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Denture Fabrication technique
Description: Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
Study: NCT01023360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and proton pump inhibitors
Description: baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week
Study: NCT04887519

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT01919801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00248807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.25 mg enalaprilat IV
Description: an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.25 mg enalaprilat IV
Description: an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head up tilt (HUT)
Description: 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
Study: NCT02093156

Intervention type: OTHER
Intervention: Bowel preparation instructions
Description: The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.

Intervention type: OTHER
Intervention: Bowel preparation instructions
Description: The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
Study: NCT00119782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A physical activity intervention combining increased daily physical activity and regular, structured exercise
Study: NCT01720901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib will be administered 250 mg one time by month, 3 times per day.
Study: NCT02679560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine HCL
Description: Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
Study: NCT03937531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Scanner
Description: PVR will be measured by using a bladder scanner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Scanner
Description: PVR will be measured by using a bladder scanner.
Study: NCT01059994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sildenafil
Description: Oral, daily, 1 week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sildenafil
Description: Oral, daily, 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral, 25mg, daily for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral, 25mg, daily for 1 week
Study: NCT01090440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
Study: NCT03637569

Intervention type: OTHER
Intervention: Measurement of triceps skinfold thickness
Description: By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
Study: NCT01854502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene and fluoride use
Description: Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
Study: NCT00765570

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Spatially Fractioned Radiation Therapy
Description: evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Group 1
Description: one treatment of Grid therapy followed by 15 treatments with standard radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation
Description: 15 Standard radiation treatments

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation
Description: standard radiation treatment
Study: NCT01854502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and use of xylitol
Description: Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
Study: NCT05299060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate adhesive (SecurePortIV®)
Description: Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
Study: NCT01436474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Study: NCT05299060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard cure
Description: The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus).
Study: NCT02283411

Intervention type: DEVICE
Group type: OTHER
Intervention: Abbott Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
Study: NCT00712634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65-A*0201 peptide vaccine
Description: Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65-A*0201 peptide vaccine
Description: Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
Study: NCT03651375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy - 3 courses of AI
Description: Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
Study: NCT01436474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Study: NCT03651375

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
Study: NCT04766528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 maximal aerobic tests
Description: Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 maximal aerobic tests
Description: Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
Study: NCT02411032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Customer gets mailing that reminds them to take their medication.
Study: NCT02893696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Various sitting time
Description: Various sitting time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Various sitting time
Description: Various sitting time
Study: NCT02411032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start
Description: Customers receive a mailing around a fresh start event: New Year's or birthday

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start
Description: Customers receive a mailing around a fresh start event: New Year's or birthday
Study: NCT01472068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inko RS Device
Description: 30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
Study: NCT04526041

Intervention type: OTHER
Group type: OTHER
Intervention: Nasofibroscopy
Description: Laryngeal exploration performed using a flexible fibrescope while singing.
Study: NCT02411032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start framing
Description: The fresh start event will be highlighted in the mailings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start framing
Description: The fresh start event will be highlighted in the mailings.
Study: NCT04526041

Intervention type: OTHER
Group type: OTHER
Intervention: Nasofibroscopy
Description: Laryngeal exploration performed using a flexible fibrescope while singing.

Intervention type: OTHER
Group type: OTHER
Intervention: Electroglottography
Description: Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.

Intervention type: OTHER
Group type: OTHER
Intervention: Electroglottography
Description: Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.

Intervention type: OTHER
Group type: OTHER
Intervention: Air flow measurement + acoustic signal recording
Description: Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)

Intervention type: OTHER
Group type: OTHER
Intervention: Air flow measurement + acoustic signal recording
Description: Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
Study: NCT00119782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Increase worksite access to both healthy foods and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Increase worksite access to both healthy foods and physical activity
Study: NCT03043287

Intervention type: BIOLOGICAL
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (BOTOX®)100 to 200 U
Study: NCT02257970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ketoprofen.
Study: NCT02926833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTE-C19
Description: A single infusion of KTE-C19 CAR-T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTE-C19
Description: A single infusion of KTE-C19 CAR-T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTE-C19
Description: A single infusion of KTE-C19 CAR-T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTE-C19
Description: A single infusion of KTE-C19 CAR-T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT04423692

Intervention type: OTHER
Intervention: labs
Description: A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
Study: NCT04099784

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
Study: NCT02801487

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT)
Description: Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
Study: NCT04533932

Intervention type: DIAGNOSTIC_TEST
Intervention: Elastography
Description: Endosonographic shear wave elastography
Study: NCT02581657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0139 Injection
Description: PE0139 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Injection